Suggestions
Dan Marks
Principal at RA Capital Management, L.P.
Dan Marks is a Board Member at CDR-Life Inc., a biotechnology company developing novel immuno-oncology therapeutics.12 He joined the company's Board of Directors in April 2022 following CDR-Life's $76 million Series A funding round.12
Professional Background
Dan Marks holds the position of Principal at RA Capital Management, a prominent healthcare investment firm.34 He joined RA Capital in 2017, bringing his expertise in life sciences and biotechnology to the company.3
Education
Marks has a strong educational background in biology and cancer research:
- BS in Biology from Yale University
- PhD in Cancer Biology from the Gerstner Sloan Kettering School of Biomedical Sciences at Memorial Sloan-Kettering Cancer Center3
Role at CDR-Life
As a Board Member at CDR-Life, Dan Marks likely contributes his expertise in biotechnology and investment to help guide the company's strategic decisions. His appointment to the board came as part of RA Capital's investment in CDR-Life's Series A funding round, where he represented RA Capital's interests.12
Industry Involvement
Dan Marks' involvement with CDR-Life and his position at RA Capital Management indicate that he plays an active role in the biotechnology and healthcare investment sectors. His background in cancer biology aligns well with CDR-Life's focus on developing novel immuno-oncology therapeutics.13
